Sight Sciences (SGHT) Shares Soar Amidst Industry Event Buzz
Sight Sciences (SGHT) Shares Soar Amidst Industry Event Buzz
Sight Sciences, Inc. (NASDAQ: SGHT) observed a notable surge in its stock value during the after-hour session on Tuesday, marking an increase of 18.20% to $6.43. This rise followed a preceding uptick of 2.45% during the regular trading session, culminating in a closing price of $5.44. The upward momentum of SGHT stock on the US stock charts coincided with the revelation of trial outcomes, which are planned to be disseminated through both oral and poster presentations at a significant industry event.
Sight Sciences, Inc.（纳斯达克股票代码：SGHT）在周二盘后交易中观察到其股票价值显著上涨，上涨18.20％，至6.43美元。此次上涨是在常规交易时段上涨2.45％之后出现的，最终收盘价为5.44美元。美国股票图表上SGHT股票的上涨势头恰逢试验结果的披露，这些结果计划在一次重要的行业活动上通过口头和海报展示进行传播。
Sight Sciences (SGHT) disclosed findings from studies into two of its proprietary technologies. SGHT's TearCare System and the OMNI Surgical System are intended to treat glaucoma and dry eye disease ("DED"). Two oral presentations and two poster displays at the next ASCRS Annual Meeting, which takes place in Boston, Massachusetts from April 5–8, are planned to highlight these discoveries.
视觉科学（SGHT）披露了对其两项专有技术的研究结果。SGHT的TearCare系统和OMNI手术系统旨在治疗青光眼和干眼病（“DED”）。计划在4月5日至8日在马萨诸塞州波士顿举行的下一届ASCRS年会上进行两次口头演讲和两次海报展览，重点介绍这些发现。
The OMNI technology is intended to improve the ability of surgeons to perform a thorough, minimally invasive, implant-free surgical surgery for individuals with primary open-angle glaucoma ("POAG"). Conversely, the TearCare technology facilitates a proprietary interventional procedure targeting diseased meibomian glands, offering localized heat therapy for adult patients grappling with evaporative DED stemming from meibomian gland dysfunction, when combined with manual expression of the meibomian glands.
OMNI技术旨在提高外科医生对原发性开角型青光眼（“POAG”）患者进行彻底、微创、无植入手术的能力。相反，TearCare技术促进了针对患病的睑板腺的专有介入手术，当与睑板腺的手动表达相结合时，为努力应对因睑板腺功能障碍引起的蒸发性DED的成年患者提供局部热疗。
At ASCRS, SGHT intends to present supplementary data reinforcing the efficacy and safety profiles of its OMNI and TearCare technologies. In addition to the existing robust corpus of clinical evidence, the company will present fresh data showcasing compelling OMNI outcomes over a 36-month period, underscoring the enduring efficacy of OMNI. Furthermore, new TearCare data will be unveiled, endorsing the utilization of TearCare technology as a primary therapeutic modality for DED.
在ASCRS，SGHT打算提供补充数据，以加强其OMNI和TearCare技术的功效和安全性。除了现有的强有力的临床证据库外，该公司还将提供新的数据，展示36个月内令人信服的OMNI结果，强调OMNI的持久疗效。此外，将公布新的TearCare数据，支持使用TearCare技术作为DED的主要治疗方式。
These findings reaffirm the notion that TearCare stands as a preferred treatment option for DED linked to meibomian gland dysfunction. Phase 1 of the SAHARA trial demonstrated that the interventional TearCare procedure delivered statistically superior and sustained improvements in tear break-up time and various measures of meibomian gland secretion compared to treatment with Restasis. In phase 2 of the study, a single TearCare procedure surpassed the outcomes achieved with six months of Restasis in terms of alleviating signs and symptoms for patients.
这些发现再次证实了这样的观点，即TearCare是与睑板腺功能障碍相关的DED的首选治疗选择。SAHARA试验的第一阶段表明，与Restasis治疗相比，介入性TearCare手术在泪液分裂时间和各种睑板腺分泌测量方面在统计学上表现出优异和持续的改善。在研究的第二阶段，单一的TearCare手术在缓解患者的体征和症状方面超过了使用六个月的Restasis所取得的结果。
译文内容由第三方软件翻译。